AR109859A1 - Inhibidor de bromodominio - Google Patents
Inhibidor de bromodominioInfo
- Publication number
- AR109859A1 AR109859A1 ARP170102935A ARP170102935A AR109859A1 AR 109859 A1 AR109859 A1 AR 109859A1 AR P170102935 A ARP170102935 A AR P170102935A AR P170102935 A ARP170102935 A AR P170102935A AR 109859 A1 AR109859 A1 AR 109859A1
- Authority
- AR
- Argentina
- Prior art keywords
- methylsulfonylphenyl
- cyclopropylmethoxy
- methylisoquinolin
- pharmaceutical composition
- inhibitor
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 5
- UWZAJPITKGWMFJ-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one Chemical compound Cn1cc(-c2cc(ccc2OCC2CC2)S(C)(=O)=O)c2ccccc2c1=O UWZAJPITKGWMFJ-UHFFFAOYSA-N 0.000 abstract 3
- 229920000642 polymer Polymers 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940125763 bromodomain inhibitor Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- -1 cyclopropylmethoxy Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000010922 spray-dried dispersion Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410756P | 2016-10-20 | 2016-10-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109859A1 true AR109859A1 (es) | 2019-01-30 |
Family
ID=62019669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102935A AR109859A1 (es) | 2016-10-20 | 2017-10-20 | Inhibidor de bromodominio |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3528810A4 (enExample) |
| JP (3) | JP7129973B2 (enExample) |
| CN (1) | CN110099685A (enExample) |
| AR (1) | AR109859A1 (enExample) |
| AU (1) | AU2017345468B2 (enExample) |
| TW (1) | TW201821062A (enExample) |
| WO (1) | WO2018075796A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10702517B2 (en) | 2015-04-22 | 2020-07-07 | Celgene Quanticel Research, Inc. | Bromodomain inhibitor |
| TW201642860A (zh) * | 2015-04-22 | 2016-12-16 | 塞爾基因定量細胞研究公司 | 布羅莫結構域抑制劑 |
| AU2019309693B2 (en) * | 2018-07-23 | 2023-03-16 | Celgene Quanticel Research, Inc. | Process for the preparation of bromodomain inhibitor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL150524A0 (en) * | 2000-01-07 | 2003-02-12 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| CN105899212A (zh) * | 2013-08-06 | 2016-08-24 | 翁科埃斯克斯有限公司 | 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法 |
| US9884806B2 (en) * | 2013-08-30 | 2018-02-06 | Icahn School Of Medicine At Mount Sinai | Cyclic vinylogous amides as bromodomain inhibitors |
| EP3290407B1 (en) * | 2013-10-18 | 2020-01-01 | Celgene Quanticel Research, Inc | Bromodomain inhibitors |
| JP2016538310A (ja) * | 2013-11-27 | 2016-12-08 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法 |
| TW201642860A (zh) * | 2015-04-22 | 2016-12-16 | 塞爾基因定量細胞研究公司 | 布羅莫結構域抑制劑 |
| CN105732624B (zh) * | 2016-01-28 | 2019-08-02 | 中国药科大学 | 吡咯[4,3,2-de]喹啉-2(1H)-酮类BRD4蛋白抑制剂的制备方法及其用途 |
-
2017
- 2017-10-19 CN CN201780076154.0A patent/CN110099685A/zh active Pending
- 2017-10-19 WO PCT/US2017/057439 patent/WO2018075796A1/en not_active Ceased
- 2017-10-19 AU AU2017345468A patent/AU2017345468B2/en not_active Ceased
- 2017-10-19 JP JP2019521064A patent/JP7129973B2/ja not_active Expired - Fee Related
- 2017-10-19 EP EP17862619.8A patent/EP3528810A4/en not_active Withdrawn
- 2017-10-20 AR ARP170102935A patent/AR109859A1/es unknown
- 2017-10-20 TW TW106136093A patent/TW201821062A/zh unknown
-
2022
- 2022-04-14 JP JP2022066855A patent/JP2022095897A/ja not_active Ceased
-
2024
- 2024-02-15 JP JP2024021416A patent/JP2024056905A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201821062A (zh) | 2018-06-16 |
| EP3528810A4 (en) | 2020-06-17 |
| AU2017345468B2 (en) | 2022-06-02 |
| WO2018075796A1 (en) | 2018-04-26 |
| JP2024056905A (ja) | 2024-04-23 |
| EP3528810A1 (en) | 2019-08-28 |
| AU2017345468A1 (en) | 2019-06-06 |
| CN110099685A (zh) | 2019-08-06 |
| JP7129973B2 (ja) | 2022-09-02 |
| JP2022095897A (ja) | 2022-06-28 |
| JP2019535671A (ja) | 2019-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17071545A (es) | Inhibidores de bromodominio | |
| CL2019001714A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer. | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| UY37098A (es) | Moduladores de ror-gamma | |
| CL2020002841A1 (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
| MX374012B (es) | Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benzoxazol. | |
| CL2016002169A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados. | |
| MX2018000412A (es) | Moduladores de diaciglicerol aciltransferasa 2 (dgat2). | |
| CO2017003838A2 (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| CO2019011546A2 (es) | Compuestos y métodos para el tratamiento de enfermedades parasitarias | |
| MX2021005038A (es) | Dispersiones solidas y composiciones farmaceuticas que comprenden un indano sustituido y metodos para la preparacion y uso de las mismas. | |
| CR20200550A (es) | Formulaciones de inmunoconjugado anti-cd79b estables | |
| CO2017007076A2 (es) | Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo | |
| CO2021007006A2 (es) | Moduladores de la expresión de irf5 | |
| CL2018001157A1 (es) | Formulación de combinación de dosis fija, eflornitina y sulindaco. | |
| ECSP18000689A (es) | Composiciones farmacéuticas sólidas para el tratamiento del vhc | |
| MX389163B (es) | Inhibidores de la isocitrato deshidrogenasa mutante y sus composiciones y metodos. | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| CU20190002A7 (es) | Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1 para el tratamiento del cáncer y composiciones farmacéuticas que los comprenden | |
| CO2020003134A2 (es) | Moduladores de la expresión de enac | |
| CL2018003013A1 (es) | Uso de un inhibidor de la acetilcolinesterasa e idalopirdina para reducir las caídas en pacientes con la enfermedad de parkinson. | |
| ECSP18008411A (es) | Composiciones farmacéuticas sólidas para el tratamiento del vhc | |
| BR112017022942A2 (pt) | composições compreendendo anakinra | |
| BR112018070497A2 (pt) | métodos e formulações farmacêuticas para tratamento de condições oculares |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |